There are few blue oceans left to explore in the life sciences industry. The therapeutic areas still free from competition are extremely difficult to tackle as the failure from aducanumab demonstrates in Alzheimer disease. That’s just one example in which a top-notch innovator fails to crack the codes of one of the few remaining areas with no treatment options.
Flocking towards orphan drugs has been the latest solution for companies to keep up with market expectations. Despite an increasing number of drugs being approved for rare diseases, the sales of orphan medicines barely accounts for 20% of the worldwide prescription sales. That makes most of the market a sea of red. This paper focuses on determining how simple technology tweaks can support the creation of a competitive advantage.
